The second quarter should bring pivotal data for Karuna and key cardiomyopathy results for Alnylam, while Ionis's eplontersen lags in amyloidosis.
There are long shots and then there is troriluzole. Biohaven will soon find out if it was wise to press on with the asset.
Kodiak, Biomarin and Argenx prepare for clinical catalysts.
A strong performance from a handful of large drug developers could not rescue the sector from a weak three months on the stock market.
Deciphera, Allakos and Uniqure are all set for important data disclosures.
Dolutegravir’s patent expiry will pile on the pressure as Gilead and Merck get on the long-acting bandwagon.
As Biogen heads towards important depression data, Sanofi looks to oncology for growth.
And Gilead has plans for its biannual injection in pre-exposure prophylaxis, too.